CER Updates:Learn more about our CER-related work:- October 28, 2009 - Presented report titled "Comparative Effectiveness Research and Personalized Medicine: From Contradiction to Synergy" at the conference on Comparative Effectiveness Research and Personalized Medicine: Science, Policy and Business hosted by the National Pharmaceutical Council and the Personalized Medicine Coalition.
- Lewin publications in health technology assessment and evidence-based medicine
- Lewin presentation to ISPOR 2009 on CER - The CER Train Has Left ... for Where? Are You on Board?
- i3 presentation on the Merits of Observational Research
- i3 webinar on CER - Comparative Effectiveness Requirements and the Payer - Recorded September 16, 2008
- i3 publications on CER:
Full reference and link to abstract |
PubMed Reference |
Harley CR, Gandhi S, Heien H, Nelson SP. The comparative effectiveness of rosuvastatin vs. other statins in patients with an increased risk of failure to reach NCEP ATP III goal. Int J Clin Pract. 2008;62(6):889-95. |
PM:18479282
|
| Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008;9(5):669-76. |
PM:18345946
|
| Stanford RH, Fuhlbrigge A, Riedel A, Rey GG, Stempel D. An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes. Curr.Med.Res.Opin. 2008:24(11):3141-8. |
PM:18838055 |
| Xin Y, Sikirica V, Schein J, Grant R, Zarotsky V, Doshi D, Benson C, Riedel A. Treatment Failure Rates and Health Care Utilization and Costs Among Patients with Community-Acquired Pneumonia Treated with Levofloxacin or Macrolides in an Outpatient Setting: A Retrospective Claims Database Analysis. Clin Ther, 2008;30(2): 358-371. |
PM:18343274 |
| Kobelt G, Berg J. Lindgren P, Jonsson B, Stawiarz L, Hillert J. Modeling the Cost-Effectiveness of a New Treatment for MS (natalizumab) compared to Current Standard Practice in Sweden. Multiple Sclerosis 2008;14(5):679-90. |
PM:18566030 |
| Lindgren P, Buxton M, Kahan T, Poulter N, Dahlöf B, Sever S, Wedel H, Jönsson B. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlopidine based treatment is cost-effective compared to an atenolol-based regimen. ASCOT Trial Investigators. Heart 2008;94(2):e4. |
PM:17916665 |
| Aballea S, Cure S, Vogelmeier C, Wiren A. A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta (2)-agonists for asthma maintenance treatment in Germany. Int J Clin Pract. 2008;62(12):1870-9. |
PM:18803555 |
| Quilici S, Abrams KR, Nicolas A, Martin M, Petit C, Lieu PL, Finnern HW. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless leg syndrome. Sleep Med. 2008;9(7):715-26. |
PM:18226947 |
Quilici S, Chancellor J, Lothgren M, Simon D, Said G, Kim Le T, Garcia-Cebrian A, Monz B. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology 2009;9:6.
|
PM:19208243 |
|
|